Understand the source comparison
Tesofensine for Weight Loss Without GLP-1: Clinical Evidence Comparison
Primary pathway Blocks NET, DAT, SERT. Increases synaptic norepinephrine, dopamine, serotonin Activates GLP-1 receptors. Delays gastric emptying, extends satiety signaling Activates GLP-1 and GIP receptors. Dual incretin effect with enhanced insulin sensitivit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Primary pathway
- Blocks NET, DAT, SERT. Increases synaptic norepinephrine, dopamine, serotonin
- Activates GLP-1 receptors. Delays gastric emptying, extends satiety signaling
- Activates GLP-1 and GIP receptors. Dual incretin effect with enhanced insulin sensitivity
- Tesofensine achieves comparable weight loss without incretin involvement
- Mean weight reduction (24 weeks)
- 10.6% at 0.5mg daily (Phase 2, The Lancet 2008)
- 14.9% at 68 weeks with 2.4mg weekly (STEP-1, NEJM 2021)
- 20.9% at 72 weeks with 15mg weekly (SURMOUNT-1, NEJM 2022)
- GLP-1 medications show greater long-term reduction; tesofensine shows faster early response
- Thermogenic effect
- +6.1% increase in 24-hour energy expenditure at 1.0mg (metabolic chamber study)
- No direct thermogenic effect. Weight loss is appetite-mediated only
- Tesofensine is the only agent with measurable metabolic rate increase
- GI adverse events
- Minimal. Nausea <5%, no vomiting or diarrhea reported in Phase 2
- Nausea 44%, vomiting 24%, diarrhea 30% during titration (STEP-1)
- Nausea 33%, vomiting 20%, diarrhea 23% during titration (SURMOUNT-1)
- Tesofensine avoids the gastric side effect profile entirely
- Cardiovascular signal
- Dose-dependent: +6–8 bpm heart rate, +3–5 mmHg systolic BP at 1.0mg
- No significant CV signal in STEP trials; CVOT ongoing
- Reduced major adverse CV events by 28% in SELECT trial (NEJM 2023)
- Tesofensine requires cardiovascular monitoring; GLP-1 medications show protective effect
- Current regulatory status
- Discontinued Phase 3 in 2008. Available as research compound only
- FDA-approved for chronic weight management (Wegovy 2.4mg weekly)
- FDA-approved for chronic weight management (Zepbound 15mg weekly)
- Tesofensine remains investigational; GLP-1 agents are standard of care